Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 845-854

  Price, Angela ^a,c   Shi, Qiao ^a,c   Morris, Donald ^b   Wilcox, M Elizabeth ^a,c   Brasher, Penny M A ^b   Rewcastle, N Barry ^d   Shalinsky, David ^e   Zou, Helen ^e   Appelt, Krzysztof ^e   Johnston, Randall N ^a   Yong, V Wee ^a   Edwards, Dylan ^a   Forsyth, Peter ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Department of Medicine ^*  (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

^e AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GELATINASES; GLIOMA; HUMANS; METALLOENDOPEPTIDASES; MICE; MICE, SCID; MICROCIRCULATION; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; ORGANIC CHEMICALS; TUMOR CELLS, CULTURED;

EID: 0032905581     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Scott, J. N., Rewcastle, N. B., Brasher, P. M., Fulton, D., Hagen, N., MacKinnon, J., Sutherland, G., Cairncross, J. G., and Forsyth, P. A. Long-term glioblastoma multiforme survivors: a population-based study. Can. J. Neurol. Sci., 25: 197-201, 1998.
2. Burger, P. C., Dubois, P. J., Schold, S. C., et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg., 58: 159-169, 1983.
3. Schiffer, D., Bertolotto, A., Giordana, M. T., et al. Spreading and invasion patterns in malignant gliomas. J. Neurooncol., 12: 270, 1992.
4. Kelly, P. J., Daumas-Duport, C., Scheithauer, B. W., Kall, B. A., and Kispert, D. B. Stereotactic histologic correlations of computed tomography and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clinic Proc., 62: 450-459, 1987.
5. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64: 327-336, 1991.
6. Kohn, E. C., and Liotta, L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res., 55: 1856-1862, 1995.
7. Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R., and Edwards, D. R. Matrix metalloproteinases and diseases of the central nervous system. Trends Neurosci., 21: 75-80, 1998.
8. Woessner, J. F. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J., 5: 2145-2154, 1991.
9. Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., and Liotta, L. A. Molecular aspects of tumor cell invasion and metastasis. Cancer (Phila.), 71: 1368-1383, 1993.
10. Mignatti, P., and Rifkin, D. B. Biology and chemistry of proteinases in tumor invasion. Physiol. Rev., 73: 161-185, 1993.
11. Pendas, A. M., Knauper, V., Puente, X. S., Llano, E., Mattei, M-G., Apte, S., Murphy, G., and Lopez-Otin, C. Identification and characterization of a novel human matrix metalloproteinase and unique structural characteristics, chromosomal location and tissue distribution. J. Biol. Chem., 272: 4281-4286, 1997.
12. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (Lond.), 370: 61-65, 1994.
13. Edwards, D. R., Beaudry, P. P., Laing, T. D., Kowal, V., Leco, K. J., and Lim, M. S. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int. J. Obesity, 20: S9-S15, 1996.
14. Bernhard, E. J., Gruber, S. B., and Muschel, R. J. Direct evidence linking expression of matrix metalloproteinase 9 (92 kDa gelatinase/ collagenase) to the metastatic phenotype in transformed rat cells. Proc. Natl. Acad. Sci. USA, 91: 4293-4297, 1994.
15. Davies, B., Waxman, J., Wasan, P., et al. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
16. Heppner, K. J., Matrisian, L. M., Jensen, R. A., and Rodgers, W. H. Expression of most MMP family members in breast cancer represents a tumor-induced host response. Am. J. Pathol., 149: 273-282, 1996.
17. Kossakowska, A. E., Urbanski, S. J., Huchcroft, S. A., and Edwards, D. R. Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol. Res., 4: 233-240, 1992.
18. MacDougall, J. R., and Matrisian, L. M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev., 14: 351-362, 1995.
19. Apodaca, G., Rutka, J. T., Bouhana, K., Berens, M. E., Giblin, J. R., Rosenblum, M. L., McKerrow, J. H., and Banda, M. J. Expression of metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res., 50: 2322-2329, 1990.
20. r 92,000 type IV collagenase in human brian tumors. Cancer Res., 53: 2208-2211, 1993.
21. Rao, J. S., Yamamoto, M., Mohanam, S., Gokaslan, Z. L., Stetler-Stevenson, W. G., Rao, V. H., Fuller, G. N., Liotta, L. A., Nicolson, G. L., and Sawaya, R. E. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin. Exp. Metastasis, 14: 12-18, 1996.
22. Costello, P. C., Del Maestro, R. F., and Stetler-Stevenson, W. G. Gelatinase A expression in human malignant gliomas. Ann. NY Acad. Sci., 732: 450-452, 1994.
23. Abe, T., Mori, T., Kohno, K., et al. Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells. Clin. Exp. Metastasis, 12: 296-304, 1994.
24. Nakano, A., Tani, E., Miyazaki, K., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J. Neurosurg., 83: 298-307, 1995.
25. Rutka, J. T., Matsuzawa, K., Hubbard, S. L., et al. Expression of TIMP-1, TIMP-2, 72-and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell invasiveness. Int. J. Oncol., 6: 877-884, 1995.
26. Nakano, A., Tani, E., Miyazaki, K., et al. Expressions of Matrilysin and stromelysin in human glioma cells. Biochem. Biophys. Res. Commun., 792: 999-1003, 1993.
27. Nakagawa, T., Kabota, T., et al. Production of matrix metalloproleinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J. Neurosurg., 81: 69-77, 1994.
28. Nakagawa, T., Kubota, T., Kubota, M., et al. Secretion of matrix metalloproteinases-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix. J. Neuro-Oncol., 28: 13-24, 1996.
29. Uhm, J. H., Dooley, N. P., Villemure, J-G., and Yong, V. W. Glioma invasion in vitro: regulation by matrix metalloproteinase-2 and protein kinase C. Clin. Exp. Metastasis, 14: 421-433, 1996.
30. Tamaki, M., McDonald, W., and Del Maestro, R. F. Release of collagen type IV degrading activity from C6 astrocytoma cells and cell density. J. Neurosurg., 84: 1013-1019, 1996.
31. Uhm, J. H., Dooley, N. P., Villemure, J-G., and Yong, V. W. Mechanisms of glioma invasion: role of matrix metalloproteinases. Can. J. Neurol. Sci., 24: 3-15, 1997.
32. Saxena, A., Robertson, J. T., Kufta, C., et al. Increased expression of gelatinase A and TIMP-2 in primary human glioblastomas. Int. J. Oncol., 7: 469-473, 1995.
33. Yamamoto, M., Mohanam, S., Sawaya, R., et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase-A activation in human malignant brain tumors in vivo and in vitro. Cancer Res., 56: 384-392, 1996.
34. Sawaya, R. E., Yamamoto, M., Gokaslan, Z. L., et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exp. Metastasis, 14: 35-42, 1996.
35. Forsyth, P. A., Dickinson-Laing, T., Gibson, A. Rewcastle, N. B., Sutherland, G., and Johnston, R. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J. Neuro-Oncol., 36: 21-29, 1998.
36. Brown, P. D., and Giavazzi, R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann. Oncol., 6: 967-974, 1995.
37. Davies, B., Brown, P. D., East, N., Crimmin, M. J., and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 53: 2087-2091, 1993.
38. Chirivi, R. G. S., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciaro, A., Brown, P. D., and Giavazzi, R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58: 460-464, 1994.
39. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W., and Brown, P. D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res., 56: 2815-2822, 1996.
40. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M. J., Brown, P. D., and Hardcastle, J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res., 55: 3629-3633, 1995.
41. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J., and Hoffman, R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-Like orthotopic model in nude mice. Cancer Res., 54: 4726-4728, 1994.
42. Low, J. A., Johnson, M. D., Bone, E. A., and Dickson, R. B. The matrix metalloproteinase inhibitor batimastat (BB94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res., 2: 1207-1214, 1996.
43. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. D., and Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst., 87: 293-298, 1995.
44. Conway, J. G., Trexler, S. J., Wakefield, J. A., Marron, B. E., Emerson, D. L., Bickett, D. M., Deaton, D. N., Garrison, D., Elder, M., McElroy, A., Willmott, N., Docherty, A. J. P., and McGeehan, G. M. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin. Exp. Metastasis, 14: 115-124, 1996.
45. Anderson, I. C., Shipp, M. A., Docherty, A. J. P., and Teicher, B. A. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res., 56: 715-718, 1996.
46. Santos, O., McDermott, C. D., Daniels, R. G., and Appelt, K. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis, 15: 499-508, 1997.
47. Shalinsky, D. R., Brekken, J., Robinson, S. R., Varki, N. V., Daniels, R., Bender, S., Zook, S., Kolis, S., Khelemsaaya, N., Gabriel, L., Wood, A. W., Webber, S., and Appelt, K. Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally-administered AG3340, a novel matrix metalloproteinase (MMP) inhibitor. Proc. Am. Assoc. Cancer Res., 39: 302, 1998.
48. Neri, A., Goggin, A., Kolis, S., Brekken, J., Khelemsaaya, N., Gabriel, L., Robinson, S. R., Webber, S., Wood, A. W., Appelt, K., and Shalinsky, D. R. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after i.v.-tail vein implantation in C57BL/6 mice. Proc. Am. Assoc. Cancer Res., 39: 302, 1998.
49. Johnson, M. R., Mullen, J. B. M., Pagura, M., Appelt, K., and Shalinsky, D. R. AG3340, a novel matrix metalloproteinase (MMP) inhibitor, decreases growth and metastases of orthotopic human lung cancer in a nude mouse rat preclinical model system. Proc. Am. Assoc. Cancer Res., 39: 302, 1998.
50. Shalinsky, D. R., Brekken, J., Zou, H., Bender, S., Zook, S., Appelt, K., Webber, S., and Varki, N. V. Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix metalloproteinase (MMP) inhibitor, AG3340, in male nude mice. Proc. Am. Assoc. Cancer Res., 39: 646, 1998.
51. Yong, V. W., and Kim, S. U. A new double labelling immunofluorescence technique for the determination of proliferation of human astrocytes in culture. J. Neurosci. Methods, 21: 9-16, 1987.
52. Guerin, C., Laterra, J., Drewes, L. R., Brem, H., and Goldstein, G. W. Vascular expression of glucose transporter in experimental brain neoplasms. Am. J. Pathol., 140: 417-425, 1992.
53. Brown, P. D. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann. NY Acad. Sci., 732: 217-221, 1994.
54. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.
55. Denhardt, D. T., Feng, B., Edwards, D. R., Cocuzzi, E., and Malyankar, U. M. On the paradoxical ability of TIMPs either to inhibit or to promote the development and progression of the malignant phenotype. In: S. P. Hawkes, D. R. Edwards, and R. Khokha (eds.), Inhibitors of Metalloproteinases in Development and Disease, in press. Lausanne, Switzerland, 1998.
56. Koop, S., Schmidt, E. E., MacDonald, I. C., Morris, V. L., Khokha, R., Grattan, M., Leone, J., Chambers, A. F., and Groom, A. C. Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc. Natl. Acad. Sci. USA, 93: 11080-11084, 1996.
57. Fowlkes, J. L., Enghild, J. J., Suzuki, K., and Nagase, H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem., 41: 25742-25746, 1996.
58. Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., and Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem., 272: 31730-31737, 1997.
59. Orlando, S., Sironi, M., Bianchi, G., Drummond, A. H., Boraschi, D., Yabes, D., and Mantovani, A. Role of metalloproteinases in the release of the IL-1 type II decoy receptor. J. Biol. Chem., 272: 31764-31769, 1997.
60. Kossakowska, A. E., Urbanski, S. J., and Edwards, D. R. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood, 77: 2475-2481, 1991.
61. Fong, K. M., Kida, Y., Zimmerman, P. V., and Smith, P. J. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res., 2: 1369-1372, 1996.
62. Visscher, D. W., Hoyhtya, M., Ottosen, S. K., Liang, C-M., Sarkar, F. H., Crissman, J. D., and Fridman, R. Enhanced expression of tissue inhibitor of metalloproteinases-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer, 59: 339-344, 1994.
63. Montgomery, A. M., and Mueller, B. M., Reisfeld, R. A., Taylor, S. M., and DeClerck, Y. A. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res., 54: 5467-5473, 1994.
64. Groft, L. L., Muzik, H., Wong, H., Rewcastle, N. B., Johnston, R. J., Edwards, D. R., and Forsyth, P. A. Tissue inhibitor of metalloproteinase expression in human malignant gliomas. Proc. Am. Assoc. Cancer Res., 39: 237, 1998.
65. DeClerck, Y. A., Perez, N., Shimada, H., Boone, T. C., Langley, K. E., and Taylor, S. M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res., 52: 701-708, 1992.
66. Imren, S., Kohn, D. B., Shimada, H., Blavier, L., and DeClerck, Y. A. Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral-medicated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res., 56: 2891-2895, 1996.
67. Gasson, J. C., Golde, D. W., Kaufman, S. E., Westbrook, C. A., Hewick, R. M., Kaufman, R. J., Wond, G. G., Tem Kossakowska, A. E., Urbanski, S. J., Leary, A. C., Brown, E. L., Orr, E. C., and Clark, S. C. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature (Lond.), 315: 768-771, 1985.
68. Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harria, T. J. R., Murphy, G., and Reynolds, J. J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (Lond.), 318: 66-69, 1985.
69. Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E., and Iwata, K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. Fed. Eur. Biochem. Soc., 298: 29-32, 1992.
70. Nemeth, J. A., Rafe, A., Steiner, M., and Goolsby, C. L. TIMP-2 growth-stimulatory activity: a concentration-and cell type-specific response in the presence of insulin. Exp. Cell Res., 224: 110-115, 1996.
71. Boujrad, N., Ogwuegbu, S. O., Garnier, M., Lee, C. H., Martin, B. M., and Papadopoulos, V. Identification of a stimulator of steroid hormone synthesis isolated from testis. Science (Washington DC), 268: 1609-1612, 1995.
72. Chesler, L., Golde, D. W., Bersch, N., and Johnson, M. D. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood, 86: 4506-4515, 1995.
73. Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2. J. Cell Sci., 707: 2373-2379, 1994.
74. Murphy, A. N., Unsworth, E. J., and Stetler-Stevenson, W. G. Tissue inhibitor or metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol., 157: 351-358, 1993.